Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Q24234347)

2

Brigid E

Hickey

1 reference

30 October 2023

Margot Lehman

3

Margot

Lehman

1 reference

30 October 2023

Daniel P Francis

4

Daniel P

Francis

1 reference

30 October 2023

Adrienne M See

5

Adrienne M

Cochrane Database of Systematic Reviews

See

1 reference

30 October 2023

7 December 2011

0 references

published in

0 references

cites work

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Adjuvant radiation therapy after radical prostatectomy for carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Erectile function outcome reporting after clinically localized prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Time trends and local variation in primary treatment of localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Estimation of a common effect parameter from sparse follow-up data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Radiotherapy after prostatectomy: is the evidence for dose escalation out there?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Salvage radiation for a rising PSA following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Using numerical results from systematic reviews in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Endorectal MRI assessment of local relapse after surgery for prostate cancer: A model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

The effect of postprostatectomy external beam radiotherapy on quality of life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

[No negative effect of percutaneous radiotherapy on continence after radical prostatectomy--the results of a prospective randomized study]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Kein negativer Einfluß der perkutanen Strahlentherapie auf die Kontinenz nach radikaler Prostatektomie — Ergebnisse einer prospektiv randomisierten Studie

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

[Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Acute Toxicity of Conventional Radiation Therapy for High-Risk Prostate Cancer in EORTC Trial 22863

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

The Long-Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021

Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007234.PUB2

7 January 2021